Age 0 3 0 3 B-age
greater 4 11 4 11 O
than 12 16 12 16 O
or 17 19 17 19 O
equal 20 25 20 25 O
to 26 28 26 28 O
6 29 30 29 30 B-lower_bound
months 31 37 31 37 I-lower_bound

Availability 0 12 38 50 O
of 13 15 51 53 O
metreleptin 16 27 54 65 B-treatment
to 28 30 66 68 O
the 31 34 69 72 O
patient 35 42 73 80 O
either 43 49 81 87 O
as 50 52 88 90 O
an 53 55 91 93 O
approved 56 64 94 102 O
drug 65 69 103 107 O
, 69 70 107 108 O
or 71 73 109 111 O
through 74 81 112 119 O
local 82 87 120 125 O
compassionate 88 101 126 139 O
use 102 105 140 143 O
or 106 108 144 146 O
expanded 109 117 147 155 O
access 118 124 156 162 O
programs 125 133 163 171 O

Generalized 0 11 172 183 B-chronic_disease
lipodystrophy 12 25 184 197 I-chronic_disease
( 26 27 198 199 O
either 27 33 199 205 O
congenital 34 44 206 216 O
or 45 47 217 219 O
acquired 48 56 220 228 O
) 56 57 228 229 O

Known 0 5 230 235 O
HIV 6 9 236 239 B-chronic_disease
infection 10 19 240 249 I-chronic_disease
or 20 22 250 252 O
HIV 23 26 253 256 O
- 26 27 256 257 O
associated 27 37 257 267 O
lipodystrophy 38 51 268 281 O

Subjects 0 8 282 290 O
who 9 12 291 294 O
have 13 17 295 299 O
a 18 19 300 301 O
known 20 25 302 307 O
hypersensitivity 26 42 308 324 O
to 43 45 325 327 O
E. 46 48 328 330 B-allergy_name
coli 49 53 331 335 I-allergy_name
derived 54 61 336 343 I-allergy_name
proteins 62 70 344 352 I-allergy_name
( 71 72 353 354 O
as 72 74 354 356 O
leptin 75 81 357 363 O
is 82 84 364 366 O
derived 85 92 367 374 O
from 93 97 375 379 O
such 98 102 380 384 O
proteins 103 111 385 393 O
) 111 112 393 394 O

